top of page
Browse by category
Search


BariPredict: Class II obesity, younger age and concurrent depression are risk factors for eating disorders in potential bariatric patients
Outcomes from the BariPredict cohort have found that 65.8% prevalence of persons at risk of an eating disorder (ED) - opting for, but not...


MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint
Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like...

Magnetic bipartition feasible, safe and effective in achieving incisionless, suture/staple-free duodeno-ileostomy
An innovative technique using a biofragmentable magnetic anastomosis system (BMAS) to effect magnetic duodeno-ileostomy (MagDI)...


WL Gore launches Gore SYNECOR preperitoneal biomaterial in Europe, the Middle East and South Africa
WL Gore & Associates (Gore) has announced that GORE SYNECOR Preperitoneal Biomaterial is now available in Europe, Middle East and South...

Journal Watch 2/4/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Early data shows Revita has potential to prevent weight regain after GLP-1 discontinuation
Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...

ENDRA reveals enhanced Strategy to enable the early detection and management of metabolic diseases facilitated by emerging GLP-1 therapies
ENDRA Life Sciences has revealed a new strategic direction to develop and deploy its Thermo-Acoustic Enhanced UltraSound system (TAEUS)...


SUMMIT: Tirzepatide benefits people with obesity, kidney disease and heart failure
Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection...


By-Band-Sleeve trial: RYGB betters LSG on weight loss and quality-of-life outcomes
Outcomes from the By-Band-Sleeve trial has confirmed the safety and effectiveness of bariatric and metabolic surgery (BMS) and that...

SOUL trial: Oral semaglutide 14 mg demonstrated superior reduction in risk of CV events
e full results from the SOUL cardiovascular outcomes trial, investigating the effects of Rybelsus (semaglutide) tablets 14 mg on reducing...
Browse by tag






bottom of page